摘要
肺癌作为世界上发病率和死亡率最高的恶性肿瘤之一,至今仍然威胁着人类的生命健康。化疗作为肺癌最基础也是最重要的治疗方式,其最为人熟知的不良反应即骨髓抑制。骨髓抑制会造成化疗患者贫血、出血、免疫机制下降,使得化疗中断或药物减量,影响化疗疗效,严重的骨髓抑制甚至会直接导致患者死亡。本文通过对肺癌患者化疗后发生骨髓抑制的定义、发生机制、治疗方式及危险因素进行阐述,进一步加强对于肺癌化疗后骨髓抑制的认识。
Lung cancer,as one of the malignant tumors with the highest morbidity and mortality in the world,is still a threat to human life and health.Chemotherapy is the most basic and important treatment for lung cancer,and the most well-known adverse reaction is myelosuppression.Myelosuppression will cause anemia,bleeding and decrease of immune mechanism in patients with chemotherapy,which will interrupt the course of chemotherapy or reduce the amount of chemotherapeutic drugs,which will effect the efficacy of chemotherapy.Severe myelosuppression can even lead to death.In this paper,the definition,mechanism,treatment and risk factors of myelosuppression in patients with lung cancer after chemotherapy are described to further strengthen the understanding of myelosuppression after chemotherapy for lung cancer.
作者
朱思遥
王赛斌
ZHU Siyao;WANG Saibin(School of Medicine,Shaoxing University,Shaoxing 312000;Respiratory and Critical Care Medicine Department,Jinhua Municipal Centeral Hospital,Jinhua 321000,China)
出处
《临床医学研究与实践》
2024年第9期195-198,共4页
Clinical Research and Practice
关键词
肺癌
化疗
骨髓抑制
危险因素
lung cancer
chemotherapy
myelosuppression
risk factor
作者简介
朱思遥(1996-),女,硕士在读。研究方向:呼吸内科方面;通讯作者:王赛斌,E-mail:saibinwang@hotmail.com.
